P337 Usefulness of drug-level monitoring in therapeutic guidance in patients with ulcerative colitis on anti-TNF-α maintenance therapy
ECCO'20 Vienna
2020
P338 The effectiveness of a standardised biologic care pathway in the management and treatment of inflammatory bowel disease
ECCO'20 Vienna
2020
P339 Assessment of DNA-thioguanine nucleotide identifies patients at risk of thiopurine-induced leukopoenia in inflammatory bowel disease
ECCO'20 Vienna
2020
P340 Comorbidity is associated with safety outcomes in vedolizumab- and ustekinumab-treated inflammatory bowel disease patientsECCO'20 Vienna
2020
P343 Efficacy of adalimumab in mild-to-moderate inflammatory bowel disease: Real-life data from single-centre experience in the long-term period
ECCO'20 Vienna
2020
P344 Effectiveness of ustekinumab in refractory Crohn’s disease: A real-life experience in a tertiary referral centre
ECCO'20 Vienna
2020
P345 Lack of anti-TNF drugs levels in fistula tissue: A reason for non-response in Crohn’s perianal fistula?
ECCO'20 Vienna
2020
P346 Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn’s disease patients
ECCO'20 Vienna
2020
P347 Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
ECCO'20 Vienna
2020
P348 Clinical outcomes and response predictors of vedolizumab treatment for anti-TNF-failed patients with IBD in Korea: A prospective multicenter cohort study
ECCO'20 Vienna
2020
P350 Perceptions of faecal microbiota transplantation in patients with ulcerative colitis
ECCO'20 Vienna
2020
P351 Spontaneous intra-abdominal abscesses in Crohn’s disease: The experience of a tertiary centre
ECCO'20 Vienna
2020
P352 Infliximab-therapy intensification based on endoscopic activity suppresses treatment interruption among patients with Crohn’s disease
ECCO'20 Vienna
2020